The use of infliximab in dermatology;Einsatzm̈glichkeiten von infliximab in der dermatologie

JDDG - Journal of the German Society of Dermatology

Volumn 5, Issue 8, 2007, Pages 655-660

  Rott, Silja ^a   Mrowietz, Ulrich ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Indications; Infliximab; Off label use

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; DAPSONE; ETANERCEPT; ETRETIN; INFLIXIMAB; ISOTRETINOIN; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ANKYLOSING SPONDYLITIS; ATOPIC DERMATITIS; BEHCET DISEASE; CROHN DISEASE; CUTANEOUS VASCULITIS; DERMATOLOGY; ECZEMA; HUMAN; LUPUS ERYTHEMATOSUS; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PYODERMA GANGRENOSUM; REVIEW; RHEUMATOID ARTHRITIS; SUBCORNEAL PUSTULAR DERMATOSIS; SUPPURATIVE HIDRADENITIS; ULCERATIVE COLITIS; VASCULITIS;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; DERMATITIS; DERMATOLOGIC AGENTS; DERMATOLOGY; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES;

EID: 34547106289     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2007.06319.x     Document Type: Review

References (37)

1. Reichrath J, Bens G, Bonowitz A, Tilgen W. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol 2005 53 : 273 83.
2. Kouklakis G, Moschos J, Leontiadis GI, Kadis S, Mpoumponaris A, Molyvas E, Minopoulos GI. Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease. A case report. Rom J Gastroenterol 2005 14 : 401 3.
3. Kaur MR, Lewis HM. Severe recalcitrant pyoderma gangrenosum treated with infliximab. Br J Dermatol 2005 153 : 689 91.
4. Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, Forbes A, Greenwood R, Probert CS. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006 55 : 505 9.
5. Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A, Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003 348 : 601 8.
6. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003 124 : 917 24.
7. Matzkies FG, Manger B, Schmitt-Haendle M, Nagel T, Kraetsch HG, Kalden JR, Schulze-Koops H. Severe septicaemia in a patient with polychondritis and Sweet's syndrome after initiation of treatment with infliximab. Ann Rheum Dis 2003 62 : 81 2.
8. Foster EN, Nguyen KK, Sheikh RA, Prindiville TP. Crohn's disease associated with Sweet's syndrome and Sjogren's syndrome treated with infliximab. Clin Dev Immunol 2005 12 : 145 9.
9. Rahier JF, Lion L, Dewit O, Lambert M. Regression of Sweet's syndrome associated with Crohn's disease after anti-tumour necrosis factor therapy. Acta Gastroenterol Belg 2005 68 : 376 9.
10. Voigtlander C, Luftl M, Schuler G, Hertl M. Infliximab (anti-tumor necrosis factor alpha antibody): a novel, highly effective treatment of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease). Arch Dermatol 2001 137 : 1571 4.
11. Grob JJ, Mege JL, Capo C, Jancovicci E, Fournerie JR, Bongrand P, Bonerandi JJ. Role of tumor necrosis factor-alpha in Sneddon-Wilkinson subcorneal pustular dermatosis. A model of neutrophil priming in vivo. J Am Acad Dermatol 1991 25 : 944 7.
12. Bonifati C, Trento E, Cordiali FP, Muscardin L, Amantea A, Carducci M. Early bot not lasting improvement of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease) after infliximab therapy: relationship with variations in cytokine levels in suction blister fluids. Clin Exp Dermatol 2005 30 : 662 5.
13. Sayinalp N, Ozcebe OI, Ozdemir O, Haznedaroglu IC, Dundar S, Kirazli S. Cytokines in Behçet's disease. J Rheumatol 1996 23 : 321 2.
14. Haugeberg G, Velken M, Johnsen V. Successful treatment of genital ulcers with infliximab in Behçet's disease. Ann Rheum Dis 2004 63 : 744 5.
15. Goossens PH, Verburg RJ, Breedveld FC. Remission of Behçet's syndrome with tumour necrosis factor alpha blocking therapy. Ann Rheum Dis 2001 60 : 637.
16. Zouboulis CC, Katsantonis J, Ketteler R, Treudler R, Kaklamani E, Hornemann S, Kaklamanis P, Orfanos CE. Adamantiades-Behçet's disease: interleukin-8 is increased in serum of patients with active oral and neurological manifestations and is secreted by small vessel endothelial cells. Arch Dermatol Res 2000 292 : 279 84.
17. Uthman IW, Touma Z, Sayyad, Salman S. Response of deep cutaneous vasculitis to infliximab. J Am Acad Dermatol 2005 53 : 353 4.
18. McCain ME, Quinet RJ, Davis WE. Etanercept and infliximab associated with cutaneous vasculitis. Rheumatology (Oxford) 2002 41 : 116 7.
19. Jacobi A, Antoni C, Manger B, Schuler G, Hertl M. Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 2005 52 : 522 6.
20. Ackermann L, Harvima IT. Mast cells of psoriatic and atopic dermatitis skin are positive for TNF-alpha and their degranulation is associated with expression of ICAM-1 in the epidermis. Arch Dermatol Res 1998 290 : 353 9.
21. Leung DY, Bieber T. Atopic dermatitis. Lancet 2003 361 : 151 60.
22. Cassano N, Loconsole F, Coviello C, Vena GA. Infliximab in recalcitrant severe atopic eczema associated with contact allergy. Int J Immunopathol Pharmacol 2006 19 : 237 40.
23. Chan JL, Davis-Reed L, Kimball AB. Counter-regulatory balance: atopic dermatitis in patients undergoing infliximab infusion therapy. J Drugs Dermatol 2004 3 : 315 8.
24. Wright RC. Atopic dermatitis-like eruption precipitated by infliximab. J Am Acad Dermatol 2003 49 : 160 1.
25. Lebwohl B, Sapadin AN. Infliximab for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 2003 49 : S275 S276.
26. Adams DR, Gordon KB, Devenyi AG, Ioffreda MD. Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol 2003 139 : 1540 2.
27. Sullivan TP, Welsh E, Kerdel FA, Burdick AE, Kirsner RS. Infliximab for hidradenitis suppurativa. Br J Dermatol 2003 149 : 1046 9.
28. Pardo J, Mercader P, Mahiques L, Sanchez-Carazo JL, Oliver V, Fortea JM. Infliximab in the management of severe pemphigus vulgaris. Br J Dermatol 2005 153 : 222 3.
29. Jacobi A, Shuler G, Hertl M. Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab. Br J Dermatol 2005 153 : 448 9.
30. Heffernan MP, Anadkat MJ. Recalcitrant cutaneous sarcoidosis responding to infliximab. Arch Dermatol 2005 141 : 910 1.
31. Barry O, Barry J, Langan S, Murphy M, Fitzgibbon J, Lyons JF. Treatment of granulomatous cheilitis with infliximab. Arch Dermatol 2005 141 : 1080 2.
32. Al Shouli S, Abouchala N, Bogusz MJ, Al Tufail M, Thestrup-Pedersen K. Toxic epidermal necrolysis associated with high intake of sildenafil and its response to infliximab. Acta Derm Venereol 2005 85 : 534 5.
33. Hunger RE, Hunziker T, Buettiker U, Braathen LR, Yawalkar N. Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment. J Allergy Clin Immunol 2005 116 : 923 4.
34. Bargagli E, Galeazzi M, Bellisai F, Volterrani L, Rottoli P. Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension. Respiration 2005.
35. Alexis AF, Strober BE. Off-label derma-tologic uses of anti-TNF-therapies. J Cutan Med Surg 2006.
36. Gupta AK, Skinner AR. A review of the use of infliximab to manage cutaneous dermatoses. J Cutan Med Surg 2004 8 : 77 89.
37. Kohler GI, Bode-Boger SM, Busse R, Hoopmann M, Welte T, Boger RH. Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther 2000 38 : 504 13.